Personalized Radiation Therapy for Glioblastoma

Recruiting in Palo Alto (17 mi)

Overseen ByRobert A. Lustig

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Abramson Cancer Center of the University of Pennsylvania

No Placebo Group

Approved in 2 jurisdictions

Trial Summary

What is the purpose of this trial?This trial is testing if giving customized higher doses of radiation can help patients with aggressive brain cancer live longer without their disease getting worse. The study will also look at side effects and overall survival.

Eligibility Criteria

This trial is for adults over 18 with a confirmed diagnosis of WHO Grade IV glioblastoma who have had most of their tumor surgically removed and are set to receive chemoradiation. Participants must be able to consent and have a Karnofsky Performance Status (KPS) score of at least 70, indicating they can care for themselves.

Inclusion Criteria

I am 18 years old or older.

I am able to care for myself but may not be able to do active work.

I have a high-grade brain tumor and am receiving chemotherapy and radiation after surgery.

Exclusion Criteria

I am currently being treated for another cancer.

Participant Groups

The study tests personalized dose-escalation radiation therapy in glioblastoma patients. It aims to see how well it works by looking at the time before the cancer worsens, side effects, where and when the cancer might come back, and overall survival rates.

1Treatment groups

Experimental Treatment

Group I: Single ArmExperimental Treatment1 Intervention

Dose-escalated radiation therapy

Personalized Radiation Therapy is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Personalized Radiation Therapy for: